Krystal Biotech, Inc. (KRYS)
341.78
-4.80
(-1.39%)
USD |
NASDAQ |
Aug 24, 16:00
341.78
0.00 (0.00%)
After-Hours: 20:00
Krystal Biotech EPS Diluted (Quarterly) : 1.786 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.786 |
| March 31, 2026 | 1.833 |
| December 31, 2025 | 1.699 |
| September 30, 2025 | 2.660 |
| June 30, 2025 | 1.289 |
| March 31, 2025 | 1.196 |
| December 31, 2024 | 1.522 |
| September 30, 2024 | 0.909 |
| June 30, 2024 | 0.5253 |
| March 31, 2024 | 0.0318 |
| December 31, 2023 | 0.3016 |
| September 30, 2023 | 2.795 |
| June 30, 2023 | -1.246 |
| March 31, 2023 | -1.762 |
| December 31, 2022 | -1.248 |
| September 30, 2022 | -1.165 |
| June 30, 2022 | -1.100 |
| March 31, 2022 | -1.990 |
| December 31, 2021 | -0.95 |
| September 30, 2021 | -0.7018 |
| June 30, 2021 | -0.7369 |
| Date | Value |
|---|---|
| March 31, 2021 | -0.744 |
| December 31, 2020 | -0.5267 |
| September 30, 2020 | -0.4884 |
| June 30, 2020 | -0.3717 |
| March 31, 2020 | -0.3077 |
| December 31, 2019 | -0.3087 |
| September 30, 2019 | -0.2471 |
| June 30, 2019 | -0.3683 |
| March 31, 2019 | -0.2851 |
| December 31, 2018 | -0.2825 |
| September 30, 2018 | -0.2593 |
| June 30, 2018 | -0.22 |
| March 31, 2018 | -0.21 |
| December 31, 2017 | -0.1352 |
| September 30, 2017 | -0.5151 |
| June 30, 2017 | -0.0741 |
| March 31, 2017 | -0.0483 |
| December 31, 2016 | -0.0612 |
| September 30, 2016 | -0.0314 |
| June 30, 2016 | -0.0196 |
| March 31, 2016 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Marker Therapeutics, Inc. | -0.0946 |
| TG Therapeutics, Inc. | 0.0495 |
| Tenaya Therapeutics, Inc. | -0.1994 |
| Cytokinetics, Inc. | -1.505 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 54.77M |
| Revenue (Quarterly) | 119.22M |
| Total Expenses (Quarterly) | 64.45M |
| Enterprise Value | 9.421B |
| Gross Profit Margin (Quarterly) | 93.46% |
| Profit Margin (Quarterly) | 45.94% |
| Earnings Yield | 2.33% |
| Operating Earnings Yield | 1.91% |
| Normalized Earnings Yield | 2.335 |